Skip to main content

Table 1 Characteristics of the study population

From: Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

  Total
n = 2.050
RA
n = 1.228
UA
n = 127
PsA
n = 398
SpA
n = 297
Age, mean (SD), years 57.8 (14.9) 61.4 (14.5) 57.8 (17.1) 54.6 (12.6) 47.5 (12.7)
Female gender, n (%) 1.354 (66) 943 (76.8) 91 (71.7) 196 (49.2) 124 (41.8)
Current smokers, n (%) 276 (16.5) 147 (14.6) 23 (19.3) 57 (18.3) 49 (20.7)
BMI, mean (SD) 25.2 (5.1) 25.0 (5.1) 25.7 (4.8) 26 (5.9) 24.8 (4.1)
 Overweight, n (%) 525 (32.5) 304 (31) 39 (31.5) 102 (35.3) 80 (36)
 Obese, n (%) 233 (14.4) 130 (13.3) 25 (20.2) 58 (20.1) 20 (9)
Hypertension, n (%) 643 (32.5) 430 (36.2) 45 (35.7) 113 (29.8) 55 (19.2)
Diabetes, n (%) 158 (8) 109 (9.2) 6 (4.8) 31 (8.2) 12 (4.2)
Disease duration, median (IQR), years 10 (5–16) 10 (5.9–18) 3.8 (2–6) 10 (5–15) 10 (5–16)
Use of PDN, n (%) 641 (31.3) 511 (41.6) 29 (22.8) 70 (17.6) 31 (10.4)
PDN dose, mean (SD), mg/day 4.3 (3.3) 4.3 (3.1) 3.3 (2.2) 4.9 (4.2) 4.7 (4.5)
 < 2.5 mg/day, n (%) 57 (8.9) 45 (8.8) 5 (17.2) 5 (7.1) 2 (6.5)
 2.5–5 mg/day, n (%) 522 (81.4) 417 (81.6) 23 (79.4) 55 (78.6) 27 (87)
 > 5 mg/day, n (%) 62 (9.7) 49 (9.6) 1 (3.4) 10 (14.3) 2 (6.5)
Use of HCQ, n (%) 382 (18.6) 284 (23.1) 72 (56.7) 21 (5.3) 5 (1.7)
Use of csDMARDs, n (%) 1.048 (51.2) 733 (59.7) 24 (19) 217 (54.5) 74 (24.9)
 MTX, n (%) 889 (43.4) 649 (52.9) 17 (13.5) 175 (44) 48 (16.2)
 SSZ, n (%) 98 (4.8) 32 (2.6) 7 (5.6) 35 (8.8) 24 (8.1)
 LFN, n (%) 53 (2.6) 45 (3.7) 0 (0) 6 (1.5) 2 (0.7)
 Others, n (%) 27 (1.3) 16 (1.3) 0 (0) 9 (2.3) 2 (0.7]
Use of b/tsDMARDs, n (%) 1.278 (62.3) 735 (59.9) 0 (0) 291 (73.1) 252 (84.8)
 TNF antagonists 743 (36.2) 339 (27.6)   186 (46.7) 218 (73.4)
 IL6-R antagonists 136 (6.6) 136 (11.1)   0 (0) 0 (0)
 IL17-IL23 antagonists 95 (4.6) 1 (0.08)   63 (15.8) 31 (10.4)
 CTLA4 Ig 146 (7.1) 145 (11.8)   1 (0.3) 0 (0)
 Rituximab 14 (0.7) 14 (1.1)   0 (0) 0 (0)
 JAK inhibitors 93 (4.5) 91 (7.4)   1 (0.3) 1 (0.3)
 IL1-R antagonists 8 (0.4) 8 (0.7)   0 (0) 0 (0)
 Others 43 (2.1) 1 (0.08)   40 (10.1) 2 (0.7)
  1. RA rheumatoid arthritis, UA undifferentiated arthritis, PsA psoriatic arthritis, SpA spondyloarthritis, BMI body mass index, PDN prednisone, HCQ hydroxychloroquine, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, SSZ sulfasalazine, LFN leflunomide, b/tsDMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs, TNF tumor necrosis factor, IL interleukin, R receptor, CTLA4 cytotoxic T lymphocyte antigen 4, JAK Janus kinase